30 Technology
Therapeutic Nitric Oxide
30 Technology is developing and defining new models of care by unlocking the potential of Nitric Oxide to treat a host of serious medical conditions. Its proprietary NO-generating liquid, RESP301, is administered via a handheld nebulizer and restores the levels of NO in the lungs with a dual action of both killing virus and bacteria and boosting the host response against these pathogenic microbes.
RESP301 is now being used in 30 Technology’s CORVIS and NOCoV2 studies in patients with lung disease, including COVID-19.
Endolytix
Endolytix is developing a new class of drugs called lyticeuticals that combines biological therapeutics with an advanced drug delivery platform to target non-tuberculous mycobacterial infections. NTM infections are poorly controlled, and often require a >2 year course of therapy that still results in a 5-year mortality rate of 25%. Endolytix’ compounds have demonstrated killing activity against a wide spectrum of NTM species, with few of the side effects seen with current therapy.
Enyo Pharma
Biomimetics for Liver Disorders
Targeting the biochemical pathways underlying behind virus-host interactions, Enyo Pharma is developing a novel class of non-bile acid FXR agonists for the treatment of Hepatitis B and nonalcoholic steatohepatitis (fatty liver disease).
Enyo's lead candidate, EYP001, has shown promising results in patients in both indications and has demonstrated a differentiated safety profile compared to other FXR agonists. This compound is currently in Phase 2 clinical trials.
F2G
A New Class of Antifungals
There are over 3 million patients, mostly immunocompromised, suffering from invasive aspergillosis infections worldwide. F2G is a Manchester-based company that has developed a novel class of antifungal agents called orotomides that are effective against invasive aspergillus, rare molds, and other fungal species.
F2G has recently completed a Phase 2 study in affected patients and have received breakthrough status and fast track designation from the FDA.
Inotrem
Modulating the Master Switch of Innate Immune Signaling
Patients with septic shock experience a physiological overreaction to immune system signaling, known as a cytokine storm, that can be deadlier than the original infection. Inotrem is a French company that has developed an inhibitor of TREM-1, the master switch of cytokine signaling.
By inhibiting this target, the positive feedback loop of uncontrolled cytokine signaling is shut down and the patient’s chances of recovery are increased. Inotrem is testing this molecule in several phase 2 clinical trials.